At close: December 20 at 4:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-192,121.0000
-194,916.0000
-178,142.0000
-121,163.0000
-74,640.0000
Investing Cash Flow
28,772.0000
-98,066.0000
-69,326.0000
18,853.0000
-96,591.0000
Financing Cash Flow
3,281.0000
208,401.0000
155,288.0000
37,681.0000
282,989.0000
End Cash Position
66,961.0000
57,276.0000
141,857.0000
234,037.0000
298,666.0000
Interest Paid Supplemental Data
--
--
--
148.0000
2,960.0000
Capital Expenditure
-10,200.0000
-16,472.0000
-8,619.0000
-7,715.0000
-29,059.0000
Issuance of Capital Stock
3,281.0000
208,394.0000
155,335.0000
37,681.0000
281,354.0000
Repurchase of Capital Stock
--
--
-47.0000
--
-72.0000
Free Cash Flow
-202,321.0000
-211,388.0000
-186,761.0000
-128,878.0000
-103,699.0000
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IMU.AX Imugene Limited
0.0380
+5.56%
LEXXW Lexaria Bioscience Corp.
0.7471
+14.94%
LXEO Lexeo Therapeutics, Inc.
6.28
+3.97%
BNTC Benitec Biopharma Inc.
11.41
-6.24%
MOLN Molecular Partners AG
5.08
-1.93%
MEOBF Mesoblast Limited
1.7300
0.00%
HUMAW Humacyte, Inc.
1.7400
+39.20%
ANIX Anixa Biosciences, Inc.
2.6900
0.00%
LGND Ligand Pharmaceuticals Incorporated
114.64
+0.61%
ARMP Armata Pharmaceuticals, Inc.
1.9500
-1.52%